A Phase I Study of LXS196 in Patients With Metastatic Uveal Melanoma.
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02601378 |
Recruitment Status :
Terminated
(The combination part of the study was terminated early due to business reasons)
First Posted : November 10, 2015
Last Update Posted : June 14, 2022
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Uveal Melanoma | Drug: LXS196 Drug: LXS196 and HDM201 | Phase 1 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 107 participants |
Allocation: | Non-Randomized |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | A Phase I, Multi-center, Open-label, Study of LXS196, an Oral Protein Kinase C Inhibitor, in Patients With Metastatic Uveal Melanoma |
Actual Study Start Date : | February 1, 2016 |
Actual Primary Completion Date : | January 7, 2022 |
Actual Study Completion Date : | January 7, 2022 |

Arm | Intervention/treatment |
---|---|
Experimental: LXS196 as a single agent
About 68 patients will be enrolled in dose escalation and expansion
|
Drug: LXS196
LXS196 as a single agent |
Experimental: LXS196 in combination with HDM201
about 44 patients to be enrolled in dose escalation and expansion
|
Drug: LXS196 and HDM201
LXS196 in combination with HDM201 |
- Incidence of dose limiting toxicities (DLTs) (Dose escalation only) [ Time Frame: Cycle 1 in dose escalation ]cycle = 28 days
- Incidence and severity of adverse events and serious adverse events, including changes in laboratory parameters, vital signs and ECGs graded as per NCI CTCAE version 4.03 (All patients) [ Time Frame: Continuously throughout the study until 30 days after treatment discontinuation ]
- Dose interruptions, reductions and dose intensity [ Time Frame: Continuously throughout the study until 30 days after treatment discontinuation ]
- Overall response rate (ORR) per RECIST version 1.1 criteria [ Time Frame: From baseline, every 2 cycles until cycle 11, then every 3 cycles afterwards until disease progression or withdrawal of consent up to 12 months ]
- Plasma LXS196 concentration-time profiles as a single agent [ Time Frame: Cycle 1 Day 1, 2, 3, 15; Cycle 2, 3, 4, 5 and 6 Day1 ]
- Modulation of signaling molecules downstream of PKC [ Time Frame: Baseline and Cycle 1 Day 15 ]
- Progression free survival (PFS) per RECIST version 1.1 criteria [ Time Frame: From baseline, every 2 cycles until cycle 11, then every 3 cycles afterwards until disease progression or withdrawal of consent up to 12 months ]
- Plasma PK parameters of LXS196 as a single agent:AUC [ Time Frame: Cycle 1 Day 1, 2, 3, 15; Cycle 2, 3, 4, 5 and 6 Day1 ]
- Plasma PK parameters of LXS196 as a single agent: Cmax [ Time Frame: Cycle 1 Day 1, 2, 3, 15; Cycle 2, 3, 4, 5 and 6 Day1 ]
- Plasma PK parameters of LXS196 as a single agent: Tmax [ Time Frame: Cycle 1 Day 1, 2, 3, 15; Cycle 2, 3, 4, 5 and 6 Day1 ]
- Plasma PK parameters of LXS196 as a single agent: t1/2 [ Time Frame: Cycle 1 Day 1, 2, 3, 15; Cycle 2, 3, 4, 5 and 6 Day1 ]
- Plasma PK parameters of LXS196 as a single agent: Racc [ Time Frame: Cycle 1 Day 1, 2, 3, 15; Cycle 2, 3, 4, 5 and 6 Day1 ]
- Plasma HDM201 concentration-time profiles [ Time Frame: Cycle 1 Day 1, 2, 3, 8; Cycle 2, 3, 4, 5 and 6 Day 1 ]
- Plasma PK parameters of HDM201: AUC [ Time Frame: Cycle 1 Day 1, 2, 3, 8; Cycle 2, 3, 4, 5 and 6 Day 1 ]
- Plasma PK parameters of HDM201: Cmax [ Time Frame: Cycle 1 Day 1, 2, 3, 8; Cycle 2, 3, 4, 5 and 6 Day 1 ]
- Plasma PK parameters of HDM201: Tmax [ Time Frame: Cycle 1 Day 1, 2, 3, 8; Cycle 2, 3, 4, 5 and 6 Day 1 ]
- Plasma PK parameters of HDM201: t1/2 [ Time Frame: Cycle 1 Day 1, 2, 3, 8; Cycle 2, 3, 4, 5 and 6 Day 1 ]
- Plasma LXS196 concentration-time profiles in combination with HDM201 [ Time Frame: Cycle 1 Day 1, 2, 3, 8; Cycle 2, 3, 4, 5 and 6 Day1 ]
- Plasma PK parameters of LXS196 in combination with HDM201:AUC [ Time Frame: Cycle 1 Day 1, 2, 3, 8; Cycle 2, 3, 4, 5 and 6 Day1 ]
- Plasma PK parameters of LXS196 in combination with HDM201: Cmax [ Time Frame: Cycle 1 Day 1, 2, 3, 8; Cycle 2, 3, 4, 5 and 6 Day1 ]
- Plasma PK parameters of LXS196 in combination with HDM201: Tmax [ Time Frame: Cycle 1 Day 1, 2, 3, 8; Cycle 2, 3, 4, 5 and 6 Day1 ]
- Plasma PK parameters of LXS196 in combination with HDM201: t1/2 [ Time Frame: Cycle 1 Day 1, 2, 3, 8; Cycle 2, 3, 4, 5 and 6 Day1 ]
- Plasma PK parameters of LXS196 in combination with HDM201: Racc [ Time Frame: Cycle 1 Day 1, 2, 3, 8; Cycle 2, 3, 4, 5 and 6 Day1 ]
- LXS196 plasma protein binding as a single agent [ Time Frame: Cycle 1 Day 1, 2, 15, 16 ]
- LXS196 plasma protein content as a single agent [ Time Frame: Cycle 1, 2, 3 and 4 Day 1 ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Key Inclusion Criteria:
- Male or female patients ≥18 years of age
- Diagnosis of uveal melanoma with histological or cytological confirmed metastatic disease. Disease must be treatment naive or have progressed (radiologically or clinically) on most recent therapy.
- Willingness to provide newly obtained tumor tissue at baseline and on treatment unless contraindicated by medical risk in the opinion of the treating physician.
- Measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as > 20 mm with conventional techniques or as >10 mm with CT scan.
- ECOG performance status ≤ 1
Key Exclusion Criteria:
- Malignant disease other than that being treated in this study.
- Symptomatic or untreated CNS metastases or spinal cord compression. Brain metastasis must be stable with verification by imaging .
- Impaired cardiac function or clinically significant cardiac diseases
- History of thromboembolic or cerebrovascular events within the last 6 months, including transient ischemic attack, cerebrovascular accident, deep vein thrombosis, or pulmonary embolism (applicable to combination part only).
- Patients who are receiving treatment with medications that cannot be discontinued prior to study entry and that are considered to be any of the following:
- known and possible risk for QT prolongation
- known to be strong inducers or inhibitors of CYP3A4/5 (for single agent part); known to be moderate to strong inducers or inhibitors of CYP3A4/5 (for combination part)
- known to be inducers or inhibitors of P-gp
- known to be substrates of CYP3A4/5 and P-gp with a narrow therapeutic index
- Patients with abnormal laboratory values, defined as any of the following:
- AST or ALT > 3 times ULN, AST or ALT > 5 times ULN for patients with liver metastases.
- Total bilirubin > 1.5 x ULN, except for patients with Gilbert's syndrome who are excluded if total bilirubin > 3.0 x ULN or direct bilirubin > 1.5 x ULN.
- Absolute neutrophil count (ANC) ≤ 1.5 x109/L.
- Platelets ≤ 100 x 109/L.
- Hemoglobin (Hgb) ≤ 90 g/L (9 g/dL).
- Creatinine > 1.5 x ULN
- Patients receiving live vaccines due to the expected bone marrow toxicity (applicable to combination part only).
- Patients treated with growth factors targeting the myeloid lineage (e.g. G-CSF, GM-CSF and M-CSF) within 2 weeks of starting study treatment. (applicable to combination part only).

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02601378
United States, New York | |
Columbia University Medical Center | |
New York, New York, United States, 10032 | |
Australia, New South Wales | |
Novartis Investigative Site | |
Westmead, New South Wales, Australia, 2145 | |
France | |
Novartis Investigative Site | |
Paris, France, 75231 | |
Netherlands | |
Novartis Investigative Site | |
Leiden, Netherlands, 2300 RC | |
Norway | |
Novartis Investigative Site | |
Oslo, Norway, 0379 | |
Spain | |
Novartis Investigative Site | |
Madrid, Spain, 28050 |
Study Director: | Novartis Pharmaceuticals | Novartis Pharmaceuticals |
Responsible Party: | Novartis Pharmaceuticals |
ClinicalTrials.gov Identifier: | NCT02601378 |
Other Study ID Numbers: |
CLXS196X2101 |
First Posted: | November 10, 2015 Key Record Dates |
Last Update Posted: | June 14, 2022 |
Last Verified: | June 2022 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
Uveal melanoma Metastatic uveal melanoma Phase I LXS196 |
PKC inhibitor HDM201 HDM2 inhibitor dose escalation |
Melanoma Uveal Neoplasms Neuroendocrine Tumors Neuroectodermal Tumors Neoplasms, Germ Cell and Embryonal Neoplasms by Histologic Type Neoplasms |
Neoplasms, Nerve Tissue Nevi and Melanomas Eye Neoplasms Neoplasms by Site Eye Diseases Uveal Diseases |